The usefulness of dapiprazole, an alpha-adrenergic blocking agent, in pigmentary glaucoma

The aim of this study was to increase understanding of the usefulness of an alpha-adrenergic blocking agent, dapiprazole 0.5% eyedrops, as an adjunct in antiglaucomatous therapy for 20 patients with pigmentary glaucoma receiving timolol 0.5% and pilocarpine 1%. After 12 months of dapiprazole treatment, the difference from the pretreatment mean intraocular pressure (IOP) value was statistically significant (P = .005). After 12 and 36 months of treatment, an hour-to-hour comparison of diurnal IOP curve values showed a statistically significant difference in all cases (P < .001). Although further investigations may be necessary to reach a definite conclusion, dapiprazole appeared to have a beneficial, stable in time effect in these patients.